Serveur d'exploration Tocilizumab

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Eléments de l'association

Région de Kantō222
N. Miyasaka6
Région de Kantō Sauf N. Miyasaka" 216
N. Miyasaka Sauf Région de Kantō" 0
Région de Kantō Et N. Miyasaka 6
Région de Kantō Ou N. Miyasaka 222
Corpus6869
\n\n\n\n \n

List of bibliographic references

Number of relevant bibliographic references: 6.
Ident.Authors (with country if any)Title
002D30 T. Takeuchi [Japon] ; Y. Kaneko [Japon] ; T. Atsumi ; Y. Tanaka ; M. Inoh ; H. Kobayashi [Japon] ; K. Amano ; M. Miyata ; Y. Murakawa ; T. Fujii ; A. Kawakami ; H. Yamanaka ; K. Yamamoto ; N. Miyasaka [Japon] ; T. MimoriOP0040 Adding Tocilizumab or Switching to Tocilizumab Monotherapy in RA Patients with Inadequate Response to Methotrexate: 24-Week Results from a Randomized Controlled Study (Surprise Study)
002E67 Y. Tanaka ; M. Harigai ; T. Takeuchi ; H. Yamanaka [Japon] ; N. Ishiguro ; K. Yamamoto [Japon] ; M. Kanazawa ; Y. Murakami ; T. Yoshinari [Japon] ; D. Baker [États-Unis] ; N. Miyasaka ; T. Koike [Japon]FRI0177 52-week results of clinical, radiographic and pharmacokinetic assessments: Golimumab, a human anti-TNF monoclonal antibody, administered subcutaneously every four weeks in patients with active rheumatoid arthritis despite methotrexate therapy
003070 Y. Tanaka ; T. Abe ; T. Takeuchi ; A. Yamamoto ; N. Miyasaka [Japon]AB0587 Safety and efficacy of abatacept(ABA) demonstrated in patients with rheumatoid arthritis(RA); 4-year data from phase III open-label, multicenter, long-term extension trial
003239 Y. Tanaka ; K. Yamamoto [Japon] ; T. Takeuchi ; H. Yamanaka [Japon] ; N. Ishiguro ; K. Eguchi ; A. Watanabe [Japon] ; H. Origasa ; T. Okamoto ; T. Shoji ; N. Miyasaka [Japon] ; T. Koike [Japon]AB0294 Long-term comprehensive disease control with certolizumab pegol regardless of concomitant dmards: results from the japanese cohort
003F52 N. Nishimoto [Japon] ; N. Miyasaka [Japon] ; K. Yamamoto [Japon] ; S. Kawai [Japon] ; T. Takeuchi [Japon] ; J. Azuma [Japon]Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
004238 J. Ogawa [Japon] ; M. Harigai [Japon] ; T. Akashi [Japon] ; K. Nagasaka [Japon] ; F. Suzuki [Japon] ; S. Tominaga [Japon] ; N. Miyasaka [Japon]Exacerbation of chronic active Epstein–Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021